These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9506790)

  • 1. Coma and respiratory failure after administering recombinant human erythropoietin: a case report.
    Borghi B; De Simone N; Bassi A; Binazzi R
    Int J Artif Organs; 1997 Dec; 20(12):715-6. PubMed ID: 9506790
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of recombinant human erythropoietin on autologous blood donation in rheumatoid arthritis patients with anaemia.
    Matsui H; Shiraishi N; Yasuda T; Nezuka T
    Clin Exp Rheumatol; 1999; 17(1):69-74. PubMed ID: 10084035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of anemia in chronically dialyzed patients].
    Moynot A
    Nephrologie; 1998; 19(3):125-7. PubMed ID: 9633055
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hemo-rheologic changes following treatment with human recombinant erythropoietin in chronic hemodialysis patients].
    Melappioni M; Giansanti R; Boemi M; Baldassari M; Baldini S; Pierangeli T; Radicioni R; Fumelli P; Panichi N
    Minerva Urol Nefrol; 1992; 44(2):155-9. PubMed ID: 1411865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of recombinant human erythropoietin in patients treated with continuous peritoneal dialysis: safety aspects.
    Bárány P; Tranaeus A; Bergström J
    Contrib Nephrol; 1991; 88():169-79; discussion 180-1. PubMed ID: 2040179
    [No Abstract]   [Full Text] [Related]  

  • 6. Human recombinant erythropoietin in the treatment of anaemia in chronic haemodialysis patients.
    Sulková S; Kvasnicka J; Kasl M; Kozlová J; Podrouzek P; Bartûsková J; Válek A
    Czech Med; 1990; 13(2-3):98-106. PubMed ID: 2245762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin and transfusions among critically ill patients.
    Bagshaw SM; Ghali WA
    JAMA; 2003 Mar; 289(12):1511; author reply 1512. PubMed ID: 12672766
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer.
    Smith RE; Jaiyesimi IA; Meza LA; Tchekmedyian NS; Chan D; Griffith H; Brosman S; Bukowski R; Murdoch M; Rarick M; Saven A; Colowick AB; Fleishman A; Gayko U; Glaspy J
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):24-30. PubMed ID: 11308271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin's role in transfusion medicine: the view from a blood bank.
    Menitove JE
    Oncology (Williston Park); 1991 Jun; 5(6):60, 65, 68. PubMed ID: 1831641
    [No Abstract]   [Full Text] [Related]  

  • 10. [Anemia and erythropoietin in critically ill patients].
    Baginski S; Körner R; Frei U; Eckardt KU
    Zentralbl Chir; 2003 Jun; 128(6):487-92. PubMed ID: 12865954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Utility of recombinant human erythropoietin on the anemia of elderly hemodialysis patients].
    Ueyama H; Nakahashi H; Sawanishi K; Kuze M; Ono T
    Hinyokika Kiyo; 1992 Dec; 38(12):1429-35. PubMed ID: 1288237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin for traumatic brain injury.
    Nichol A; Little L; French C
    JAMA; 2014 Nov; 312(18):1928-9. PubMed ID: 25387193
    [No Abstract]   [Full Text] [Related]  

  • 13. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy.
    Glaspy J; Jadeja JS; Justice G; Kessler J; Richards D; Schwartzberg L; Rigas J; Kuter D; Harmon D; Prow D; Demetri G; Gordon D; Arseneau J; Saven A; Hynes H; Boccia R; O'Byrne J; Colowick AB
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):17-23. PubMed ID: 11308270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin for traumatic brain injury--reply.
    Robertson CS; Yamal JM; Tilley BC
    JAMA; 2014 Nov; 312(18):1929. PubMed ID: 25387194
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cutaneous reactions to treatment with recombinant human erythropoietin].
    Schröder-Kolb B
    Derm Beruf Umwelt; 1990; 38(1):12-3. PubMed ID: 2139602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of the anemia of hemodialysis patients with recombinant human erythropoietin.
    Schaefer RM; Kuerner B; Zech M; Denninger G; Borneff C; Heidland A
    Int J Artif Organs; 1988 Jul; 11(4):249-54. PubMed ID: 3410565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.
    Eschbach JW; Egrie JC; Downing MR; Browne JK; Adamson JW
    N Engl J Med; 1987 Jan; 316(2):73-8. PubMed ID: 3537801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients.
    MacLaren R; Sullivan PW
    Value Health; 2005; 8(2):105-16. PubMed ID: 15804319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
    Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
    J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comments on: erythropoietin administration and transfusion regimen after traumatic brain injury].
    Höllig A; Coburn M
    Anaesthesist; 2014 Oct; 63(10):793-4. PubMed ID: 25142317
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.